Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial

By sjmartinez • August 22, 2022

Ma TM, Ballas LK, Wilhalme H, Sachdeva A, Chong N, Sharma S, Yang T, Basehart V, Reiter RE, Saigal C, Chamie K, Litwin MS, Rettig MB, Nickols NG, Yoon SM, Smith L, Gao Y, Steinberg ML, Cao M, Kishan AU. Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2022 Aug 22:S0360-3016(22)03160-1. doi: 10.1016/j.ijrobp.2022.08.041. Epub ahead of print. PMID: 36007724.

MRI-guided radiotherapy, Prostate cancer, Stereotactic Body Radiation Therapy, postprostatectomy radiation, quality of life, radical prostatectomy,

Tags: Hematology/Oncology, MRI-guided radiotherapy, postprostatectomy radiation, prostate cancer, Publications, Quality of Life, radical prostatectomy, Stereotactic Body Radiation Therapy

Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary

Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P,[...]

Immunotherapy for hormone receptor-positive HER2-negative breast cancer

Cardoso F, Hirshfield KM, Kraynyak KA, Tryfonidis K, Bardia A. Immunotherapy for hormone receptor‒positive HER2-negative breast cancer. NPJ Breast Cancer. 2024 Dec 6;10(1):104. doi: 10.1038/s41523-024-00704-9.[...]

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán[...]